

[54] **SOLID STATE OPHTHALMIC MEDICATION DELIVERY METHOD**

[76] Inventors: **Heskel M. Haddad**, 1200 Fifth Ave., New York, N.Y. 10029; **Spiro P. Loucas**, 16 Toni Ct., Plainview, N.Y. 11803

[22] Filed: **Jan. 22, 1974**

[21] Appl. No.: **435,475**

Related U.S. Application Data

[63] Continuation of Ser. No. 246,661, April 24, 1972.

[52] **U.S. Cl.**..... **424/22**, 128/260, 424/14, 424/16, 424/19, 424/180, 424/273, 424/361, 424/362

[51] **Int. Cl.**..... **A61k 27/12**

[58] **Field of Search** 128/260; 424/14, 16, 19-22, 424/180, 361, 362, 273

[56] **References Cited**

UNITED STATES PATENTS

273,410	3/1883	Wadleish	128/260
3,075,527	1/1963	Bechtold	128/260
3,450,814	6/1969	Bechtold et al.....	424/180
3,618,604	11/1971	Noss	128/260
3,640,741	2/1972	Btos	106/170

OTHER PUBLICATIONS

Iakovlov, *Vistn. Oftal*, Nov.-Dec., 1966, pp. 40-42, The Use of Pilocarpine in a Polyvinyl Alcohol Film for the Treatment of Glaucomators.
Krishna et al., *Am. J. Ophthal* 57; 94-106, (1964), Polyvinyl Alcohol as an Ophthalmic Vehicle.

Maichuk, *Antibiotik* 112(5); 432-435, (1967), Polyvinyl Alcohol Films with Antibiotics in the Therapy of Eye Infections.

Anderson et al., *Am. J. Ophthal* 51; 1200-1203, (1961), Tissue Response to Polyvinyl Alcohol Implants in Rabbits.

Haas et al., *Am. J. Ophthal* 54; 21-23, (1962), The Effect of Methylallulose on Responses to Solutions of Piloarpine.

Dohlman et al., *Annals. Ophthal*, Oct., 1972, pp. 823-832, A New Ocular Insert Device for Continuous Constant Rate Delivery of Medication to the Eye.

Loucas et al., *J. Pharm. Sci.* 61(6), pp. 985-986, June, 1972, Solid-State Ophthalmic Dosage Systems in Effecting Prolonged Release of Pilocarpine in the Cul de Sac.

Haddad, et al., *Bull. et Mem. Soc. Fr. Ophthal.* 84; 621-624, (1971), Les Derives de l'Acide Polyuro-nique Prolongeant le Transport de la Pilocarpine.

Primary Examiner—Shep K. Rose

Attorney, Agent, or Firm—Fitzpatrick, Cella, Harper & Scinto

[57] **ABSTRACT**

A method of delivering a medicament to the eye in solid form is described. The duration of miotic, mydriatic or other pharmacological activity is prolonged by the direct insertion of solid dosage forms of pharmacologically active compounds in the cul-de-sac of the conjunctiva.

13 Claims, 3 Drawing Figures